Home | Investor Relations
Stock Quote (NASDAQ: NSTG)
- 0.42
Day High:
Day Low:
4:00 PM ET on May 27, 2015
Delayed at least 20 minutes.
Provided by eSignal.

Search Investor Relations

Investor Relations

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in hundreds of peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

Key Publication

ARTICLEAug 01, 2013
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Dowsett M. et al., Journal of Clinical Oncology August 1, 2013 vol. 31 no. 22 2783-2790

View all »Events & Webcasts

WEBCASTMay 20, 2015 at 8:30 AM ET
UBS Global Healthcare Conference
WEBCASTMay 06, 2015 at 4:30 PM ET
Nanostring 2015 First Quarter Financial Results
PDF View Transcript   280.1 KB   Add to Briefcase
WEBCASTMar 04, 2015 at 8:40 AM ET
Cowen 35th Annual Health Care Conference
PDF View Presentation   1.7 MB   Add to Briefcase